{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:01:15Z","timestamp":1792789275914,"version":"4.5.0"},"reference-count":18,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Laboratoires SMB SA","id":[{"id":"https:\/\/ror.org\/03jbf2g44","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>Background: Given the increasing prevalence of dyslipidemia and multimorbidity in the older patient population, the lack of safety data on combined statin\u2013fenofibrate therapy in this age group represents a critical gap. The post hoc subgroup analysis of the POSE study addresses this issue. Materials and Methods: The POSE study was a 3-year, real-world, observational, comparative, non-interventional study conducted in Europe. Patients with mixed dyslipidemia treated either by a fixed-dose combination of pravastatin 40 mg\/fenofibrate 160 mg or a moderate-intensity statin monotherapy were enrolled. Safety outcomes included the occurrence of renal or urinary disorders, musculoskeletal or connective tissue disorders, hepatobiliary disorders, cholelithiasis, thromboembolic events, pancreatitis, worsening diabetes mellitus, elevated blood homocysteine levels, interstitial pneumopathy, phototoxicity, and fatal or non-fatal cardiovascular events. Laboratory parameters related to lipid control and renal, muscular, and hepatic functions were additionally evaluated. The post hoc analysis focused on a subgroup of patients aged 75 years and older. Results: A total of 458 patients were included in the analysis. The majority had hypertension (79.3%) and diabetes mellitus (55.0%). Over the 3-year study period, the incidence rate of composite safety events was numerically higher with the combination, though this did not reach statistical significance (RR = 2.18 [95% CI = 0.99\u20134.81]). Renal and urinary disorders were more frequent with the combination (5.5% vs. 0.8%), whereas musculoskeletal disorders, aggravated diabetes mellitus, and cardiovascular events showed no significant difference between groups, as the 95% confidence interval included 1. Globally, there were no significant differences regarding evolution of the hepatic, muscle, and renal biological parameters. From baseline to Year 3, TG levels decreased by 44.3% with pravastatin\/fenofibrate and by 10.7% with statin monotherapy, while HDL-C levels increased by 26.5% and 0.4%, respectively. Conclusions: This real-life observational post hoc subgroup analysis suggests that in patients aged 75 years and older with mixed dyslipidemia at high or very high CV risk, pravastatin 40 mg\/fenofibrate 160 mg demonstrates an acceptable long-term safety profile. The combination offers additional TG lowering and HDL-C improvement beyond moderate-intensity statin monotherapy, without a significant increase in overall safety events over three years.<\/jats:p>","DOI":"10.3390\/geriatrics11050135","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:50:27Z","timestamp":1789566627000},"page":"135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Long-Term Safety of Statin\u2013Fibrate Combination Therapy in Older Patients (\u226575 Years): A European Cohort Analysis"],"prefix":"10.3390","volume":"11","author":[{"given":"Nikolaos","family":"Papadopoulos","sequence":"first","affiliation":[{"name":"Cardiology Clinic, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-1875","authenticated-orcid":false,"given":"John","family":"Doupis","sequence":"additional","affiliation":[{"name":"Diabetes Clinic and Clinical Research Center, Iatriko Paleou Falirou Medical Center, 17562 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Theodoros","family":"Angelopoulos","sequence":"additional","affiliation":[{"name":"Internal Medicine and Diabetes, Iatriko Paleou Falirou Medical Center, 17562 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Elias","family":"Tsougos","sequence":"additional","affiliation":[{"name":"6th Cardiology Department, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-4184","authenticated-orcid":false,"given":"Manuel Suarez","family":"Tembra","sequence":"additional","affiliation":[{"name":"Lipids and Cardiovascular Risk Unit, San Rafael Hospital, 15006 A Coruna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-495X","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Diaz","sequence":"additional","affiliation":[{"name":"Lipids and Cardiovascular Risk Unit, Hospital Abente y Lago, 15006 A Coruna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-2710","authenticated-orcid":false,"given":"Diego Bellido","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition, University Hospital of Ferrol, 15405 A Coruna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-839X","authenticated-orcid":false,"given":"Maria Antonia","family":"Sanchez-Calavera","sequence":"additional","affiliation":[{"name":"Casablanca Health Centre, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Juan Carlos Garcia","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Primary Care Management, Centro de Salud Universitario Dr. Mendiguch\u00eda Carriche, Servicio Madrile\u00f1o de Salud, 28914 Leganes, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Antonio Robles","family":"Iniesta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital General de Requena, 46340 Requena, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Sonia","family":"Redondo","sequence":"additional","affiliation":[{"name":"Centro de Salud El Espinillo, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7902-5504","authenticated-orcid":false,"given":"Antonio","family":"Ruiz Garcia","sequence":"additional","affiliation":[{"name":"Lipid and Cardiovascular Prevention Unit, Pinto University Health Centre, 28320 Pinto-Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5784-8737","authenticated-orcid":false,"given":"Jose Antonio","family":"Diaz","sequence":"additional","affiliation":[{"name":"Internal Medicine, Clinico Universitario, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Daniel Zambon","family":"Rados","sequence":"additional","affiliation":[{"name":"Lipids and Artherosclerosis Unit Department of Internal Medicine, Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Pere Alvarez","family":"Garcia","sequence":"additional","affiliation":[{"name":"Hayge Private Foundation, 08840 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Daiana","family":"Ibarretxe","sequence":"additional","affiliation":[{"name":"Vascular Medicine and Metabolism Unit, Hospital Universitari Sant Joan de Reus, 43204 Tarragona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Belen","family":"Fraille","sequence":"additional","affiliation":[{"name":"Trinitat Health Centre, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Jose Maria Tirado","family":"Moliner","sequence":"additional","affiliation":[{"name":"Centro de Salud de Burriana, 12530 Castellon, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Luis Enrique Morales","family":"Cobo","sequence":"additional","affiliation":[{"name":"Centro de Salud Universitario Las Am\u00e9ricas, Parla, 28983 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Maria Jesus","family":"Barreda","sequence":"additional","affiliation":[{"name":"Centro de Salud Paulino Prieto, 33009 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Juan Luis","family":"Frigola","sequence":"additional","affiliation":[{"name":"Cap Sant Pere de Reus, Institut Catal\u00e0 de la Salut, 43202 Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-0091","authenticated-orcid":false,"given":"Fernando","family":"Gomez Peralta","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Unit, Segovia General Hospital, 40002 Segovia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Moreno","sequence":"additional","affiliation":[{"name":"Centro de Salud Universitario Las Am\u00e9ricas, Parla, 28983 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Nuria","family":"Font","sequence":"additional","affiliation":[{"name":"Requena Hospital, 46340 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6696-1600","authenticated-orcid":false,"given":"Antonio","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Alta Resolucion de Utrera Hospital, 41710 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Jorge Manuel Romero","family":"Requena","sequence":"additional","affiliation":[{"name":"Internal Medicine, Perpetuo Socorro Hospital, 06010 Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Jos\u00e9","family":"Porta","sequence":"additional","affiliation":[{"name":"Sagasta Ruisenores Health Centre, 50006 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Stephanie","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Laboratoires SMB SA, Clinical Department, 1080 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-2636","authenticated-orcid":false,"given":"Sophie","family":"De Niet","sequence":"additional","affiliation":[{"name":"Laboratoires SMB SA, Clinical Department, 1080 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40265-025-02182-0","article-title":"Lipid-lowering therapy and cardiovascular prevention in elderly","volume":"85","author":"Baratta","year":"2025","journal-title":"Drugs"},{"key":"ref_2","first-page":"25","article-title":"Management of dyslipidemia in older adults","volume":"84","author":"Orkaby","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bao, A., and Karalis, D.G. (2025). Statin Therapy for Primary and Secondary Prevention in Older Adults. Curr. Atheroscler. Rep., 27.","DOI":"10.1007\/s11883-024-01257-9"},{"key":"ref_4","unstructured":"GBD 2023 Causes of Death Collaborators (2025). Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet, 406, 1811\u20131872."},{"key":"ref_5","unstructured":"(2019). Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, 393, 407\u2013415."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"The ACCORD Study Group (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med., 362, 1563\u20131574.","DOI":"10.1056\/NEJMoa1001282"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40801-024-00426-1","article-title":"Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database","volume":"11","author":"Sobukawa","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Papadopoulos, N., Arvaniti, E., Angelopoulos, T., Tziomalos, K., Tembra, M.S., Diaz, J.L., De Niet, S., Da Silva, S., and Doupis, J. (2024). A European, observational 3-year cohort comparative study on the safety of the fixed-dose combination pravastatin 40 mg\/fenofibrate 160 mg vs. statin alone in real clinical practice. Pharmacoepidemiol. Drug Saf., 33.","DOI":"10.1002\/pds.70047"},{"key":"ref_10","unstructured":"ESC\/EAS Task Force (2019). 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 290, 140\u2013205."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.amjcard.2010.05.005","article-title":"Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy","volume":"106","author":"Farnier","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2011.626398","article-title":"Long-term safety and efficacy of fenofibrate\/pravastatin combination therapy in high-risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy","volume":"27","author":"Farnier","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11630820-000000000-00000","article-title":"Safety of a fixed-dose combination of fenofibrate\/pravastatin 160 mg\/40 mg in patients with mixed hyperlipidaemia: A pooled analysis from a database of clinical trials","volume":"32","author":"Farnier","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"ref_14","unstructured":"European Medicines Agency (EMA) (2013). Assessment Report: Cholib (Fenofibrate\/Simvastatin), European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cholib-epar-public-assessment-report_en.pdf?utm_source=chatgpt.com."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, ACCORD Eye Study Group, Chew, E.Y., Ambrosius, W.T., Davis, M.D., Danis, R.P., Gangaputra, S., Greven, C.M., Hubbard, L., and Esser, B.A. (2010). Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med., 363, 233\u2013244.","DOI":"10.1056\/NEJMoa1001288"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ku, E.J., Kim, B., Han, K., Lee, S.-H., and Kwon, H.-S. (2024). Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT. Cardiovasc. Diabetol., 23.","DOI":"10.1186\/s12933-024-02422-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10654-025-01346-2","article-title":"Why do women live longer than men, but spend more time in poor health? A decomposition analysis of the gender gap in unhealthy life years across Europe","volume":"41","author":"Minagawa","year":"2026","journal-title":"Eur. J. Epidemiol."}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/11\/5\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:38:32Z","timestamp":1789569512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/11\/5\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["geriatrics11050135"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics11050135","relation":{},"ISSN":["2308-3417"],"issn-type":[{"value":"2308-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}